Blood Plasma Derivatives Market Growth and Forecast by 2028

[Research Report] The blood plasma derivatives market is expected to reach US$ 51,119.24 million by 2028 from US$ 29.886.12 million in 2022; it is estimated to record a CAGR of 9.4% from 2022 to 2028.  

Plasma derivatives are obtained from explicit plasma proteins by the cycle of fractionation. Blood plasma derivatives contain a high amount of proteins, salts, minerals, hormones, vitamins, and protease inhibitors. Thus, they are commonly used to destroy viruses that trigger bleeding disorders, hepatitis B, hepatitis C, hemophilia A, immunodeficiency, hypogammaglobulinemia, hemophilia B, and human immunodeficiency virus.

The blood plasma derivatives market is segmented on the basis of type, application, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the market, emphasizing on parameters such as market trends, technological advancements, and market dynamics, along with the competitive landscape analysis of the world's leading market players.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Blood Plasma Derivatives Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Market Insights – Blood Plasma Derivatives Market

Increasing Usage of Immunoglobulin G in Multiple Treatments to Offer Opportunities for Blood Plasma Derivatives Market in Coming Years

Immunoglobulin G (IgG) therapies are highly used to treat primary immune deficiency caused by genetic defects. The demand for IgG has been increasing steadily for the last few years due to the increasing awareness of IgG therapy. Based on controlled trials done by Network Meta Analysis (NMA), IgG therapy has been approved for the treatment of guillain-barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and dermatomyositis. IgG therapies are also effective for treating myasthenia gravis exacerbations and stiff-person syndrome. In addition, it provides convincing efficacy in autoimmune disorders such as epilepsy, neuromyelitis, and autoimmune encephalitis.

• In 2022, Grifols entered an agreement with Canadian Blood Services. This agreement accelerate self-sufficiency in immunoglobulins for Canada. Under the agreement, Grifols will work with Canadian Blood Services to gradually increase the sourcing of plasma in Canada to reach volumes to 2.4 million grams of Ig medicines annually by 2026.
• In 2021, the Food and Drug Administration (FDA) approved Cutaquig for medical use. It is used as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients of 2 years and above. Cutaquig is a ready-to-use immune globulin solution for subcutaneous infusion. The product is available in 1g, 1.65g, 2g, 3.3g, 4g, or 8g single-use vials.
• In August 2020, Kedrion Biopharma (Italy) began improving a plasma-inferred treatment for treating COVID-19 patients. The treatment could be accessible to patients in three to a half years.

A large proportion of IgG is used in specialties outside of immunology, such as oncology, neurology, hematology, and rheumatology. Compared to all, neurology is the fastest-growing specialty in the global market. The Immunoglobulin G market growth is attributed to its approval for on-label use for chronic inflammatory demyelinating polyneuropathy (CIDP) followed by its off-label use in secondary immune deficiencies caused by lymphoma, myeloma, and leukemia and the certain immunosuppressive therapies esp. B-cell targeting therapies. Thus, the wide range of IgG usage in multiple treatments for on-label and off-label prescriptions will drive IgG demand across the world in the coming years.

End User Insights

Based on end user, the global blood plasma derivatives market is segmented into hospitals, clinics, and others. The hospitals segment held the largest market share in 2022 and is anticipated to register the highest CAGR during the forecast period. The increasing number of hospital admissions and a rising prevalence of von Willebrand disease, immunodeficient disorders, and hemophilia are projected to drive market growth for the hospital segment during the forecast period. Moreover, emerging nations are witnessing huge demand for advanced hospital settings to cope with the increasing patient pool and rising public health concerns. Furthermore, various immunoglobulin replacement therapies are conducted in hospitals to observe the doses and adverse events related to the therapy and to monitor clinical outcomes of the product. Hospitals are primary centers for providing immunoglobulin replacement therapies, which are being developed using new technologies. Patients receiving immune globulin therapies in hospitals perceive the advantages of greater safety, closer monitoring, and support from health professionals and experts. Thus, benefits provided by hospitals, such as proper patient-centric care and availability of reimbursement facilities, are expected to fuel market growth for the segment during the forecast period.

Product launches and mergers and acquisitions are among the highly adopted strategies by the global blood plasma derivatives market players. A few of the recent key product developments are listed below:

• In April 2022, Grifols announced the acquisition completion of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG. Tiancheng (Germany) Pharmaceutical Holdings AG is a German company that holds 89.88% of the ordinary shares and 1.08% of the preferred shares of Biotest AG. Following the Public Takeover Offer (PTO) completion and the acquisition closing, Grifols controls 96.20% of the voting rights and holds 69.72% of the share capital of Biotest AG.

Blood Plasma Derivatives Market Regional Insights

The regional trends and factors influencing the Blood Plasma Derivatives Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Blood Plasma Derivatives Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Blood Plasma Derivatives Market Report Scope

Blood Plasma Derivatives Market Players Density: Understanding Its Impact on Business Dynamics

The Blood Plasma Derivatives Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Blood Plasma Derivatives Market are:

1. Grifols SA
2. SK Plasma Co Ltd
3. Octapharma AG
4. Monobind Inc
5. Intas Pharmaceuticals Ltd

Disclaimer: The companies listed above are not ranked in any particular order.

Blood Plasma Derivatives – Market Segmentation

Based on type, the blood plasma derivatives market is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The market for the immunoglobulin segment is further segmented into IgG, IgM, IgA, IgD, and IgE. By application, the blood plasma derivatives market is segmented into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease, and other applications. The market, by end user, is segmented into hospitals, clinics, and others. Based on geography, the blood plasma derivatives market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Company Profiles – Blood Plasma Derivatives Market

• Grifols, S.A.
• SK Plasma Co., Ltd.
• Fusion Healthcare
• Biotest AG
• Green Cross Corp
• Kedrion
• LFB S.A.
• Octapharma AG
• CSL Limited
• Takeda Pharmaceutical Company Limited